


## MnTBAP chloride

<b>Cat. No.:</b>	HY-126397		
<b>CAS No.:</b>	55266-18-7		
<b>Molecular Formula:</b>	C <sub>48</sub> H <sub>28</sub> ClMnN <sub>4</sub> O <sub>8</sub>		
<b>Molecular Weight:</b>	879.15		
<b>Target:</b>	NF-κB		
<b>Pathway:</b>	NF-κB		
<b>Storage:</b>	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



### BIOLOGICAL ACTIVITY

<b>Description</b>	MnTBAP chloride is a superoxide dismutase (SOD) mimetic and peroxynitrite scavenger. MnTBAP chloride is a manganic porphyrin complex and has anti-oxidative property. MnTBAP chloride mediates anti-inflammatory effects through upregulation of BMPR-II and inhibition of the NFκB signaling. MnTBAP chloride has the potential for the fibrotic response in chronic kidney diseases (CKDs) research <sup>[1][2]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	NFκB								
<b>In Vitro</b>	<p>MnTBAP chloride (pretreated 1.14 μM before TGF-β1 of 10 ng/mL) partially but significantly restores E-cadherin reduction and suppresses the induction of α-SMA and vimentin in immortalized mouse proximal tubular cells (mPTCs)<sup>[1]</sup>.</p> <p>MnTBAP chloride (50 μM; 6 hours) increases BMPR-II mRNA by 1.3-fold at 2 h, but does not affect protein expression of BMPR-II during a time course of 16 h in HUVECs. MnTBAP chloride increases phosphorylation of Smad 1/5, suggesting modulation of the BMP signaling pathway<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
<b>In Vivo</b>	<p>MnTBAP chloride (10 mg/kg; IP; three times per week for twelve weeks) attenuates renal fibrosis in 5/6 Nx mice<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" data-bbox="341 1417 1518 1690"> <tr> <td>Animal Model:</td> <td>C57BL/6J mice with 5/6 nephrectomy (Nx)<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>IP; three times per week for twelve weeks</td> </tr> <tr> <td>Result:</td> <td>Attenuated renal fibrosis in 5/6 Nx mice and reduced protein expressions of fibronectin, collagen III in remnant kidneys.</td> </tr> </table>	Animal Model:	C57BL/6J mice with 5/6 nephrectomy (Nx) <sup>[1]</sup>	Dosage:	10 mg/kg	Administration:	IP; three times per week for twelve weeks	Result:	Attenuated renal fibrosis in 5/6 Nx mice and reduced protein expressions of fibronectin, collagen III in remnant kidneys.
Animal Model:	C57BL/6J mice with 5/6 nephrectomy (Nx) <sup>[1]</sup>								
Dosage:	10 mg/kg								
Administration:	IP; three times per week for twelve weeks								
Result:	Attenuated renal fibrosis in 5/6 Nx mice and reduced protein expressions of fibronectin, collagen III in remnant kidneys.								

### REFERENCES

- [1]. Jing Yu, et al. MnTBAP Therapy Attenuates Renal Fibrosis in Mice With 5/6 Nephrectomy. *Oxid Med Cell Longev.* 2016;2016:7496930.
- [2]. Qian Zhou, et al. MnTBAP Increases BMPR-II Expression in Endothelial Cells and Attenuates Vascular Inflammation. *Vascul Pharmacol.* 2016 Sep;84:67-73.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA